Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV
Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV
Sponsor: AbbVie
This observational or N/A phase trial investigates Hepatitis C and is currently actively recruiting participants. AbbVie leads this study, which shows 4 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
4 versions recorded-
Apr 28, 2026 — Present [daily]
Recruiting
Status: Not Yet Recruiting → Recruiting · Phase: PHASE1/PHASE2 → None
-
Feb 2026 — Apr 2026 [monthly]
Not Yet Recruiting PHASE1/PHASE2
-
Sep 2025 — Feb 2026 [monthly]
Not Yet Recruiting PHASE1/PHASE2
-
Jul 2025 — Sep 2025 [monthly]
Not Yet Recruiting PHASE1/PHASE2
First recorded
Eligibility Summary
This is a Phase I/II, multi-site, open-label, single arm study to describe the pharmacokinetics (PK) and safety of glecaprevir/pibrentasvir (GLE/PIB) initiated during pregnancy in women with hepatitis C virus (HCV) infection (acute or chronic) with or without HIV and to evaluate safety for their infants through 10 weeks postpartum.
Contact Information
- AbbVie
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Mental Health (NIMH)
For direct contact, visit the study record on ClinicalTrials.gov .